Cornerstone Pharmaceuticals (02616) is now up nearly 4%. As of press release, it is up 3.7% to HK$1.12, with a turnover of HK$2.7921 million.
The Zhitong Finance App learned that Cornerstone Pharmaceuticals (02616) is now up nearly 4%. As of press release, it has risen 3.7% to HK$1.12, with a turnover of HK$2.7921 million.
According to the news, Cornerstone Pharmaceuticals announced that CS5001 (ROR1 ADC), the company's flagship product with R&D pipeline 2.0, the latest data from the first 1a/b global multi-center human study to treat patients with advanced solid tumors and lymphoma will be presented in the form of a poster at this year's American Society of Clinical Oncology (ASCO) annual meeting. This year's ASCO Annual Meeting will be held from May 31 to June 4 in Chicago, USA.
According to reports, in October 2020, Cornerstone Pharmaceuticals and LEGOChem Biosciences, Inc. (LCB) reached a licensing agreement for the development and commercialization of CS5001. CS5001 was initially co-synthesized by leading Korean biotech companies LCB and ABL Bio. Under the terms of the agreement, Cornerstone Pharmaceuticals obtained exclusive development and commercialization rights for CS5001 in other regions of the world other than Korea.